These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25818758)

  • 1. Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.
    Gaertner S; Cordeanu EM; Mirea C; Stephan D
    Int J Cardiol; 2015; 186():141-2. PubMed ID: 25818758
    [No Abstract]   [Full Text] [Related]  

  • 2. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.
    Barrios V; Górriz JL
    J Comp Eff Res; 2015 Nov; 4(6):651-64. PubMed ID: 26388302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 4. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants: to switch or not to switch?
    Lugthart S; Leebeek FW
    Neth J Med; 2015 Oct; 73(8):359-61. PubMed ID: 26478544
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.
    Béné J; Dubart AE; Senis C; Auffret M; Caron J; Gautier S
    J Mal Vasc; 2014 Jul; 39(4):248-55. PubMed ID: 24889788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
    Steurer J
    Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitamin K antagonists and cognitive impairment: results from a cross-sectional pilot study among geriatric patients.
    Annweiler C; Ferland G; Barberger-Gateau P; Brangier A; Rolland Y; Beauchet O
    J Gerontol A Biol Sci Med Sci; 2015 Jan; 70(1):97-101. PubMed ID: 25151653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent changes in practice guidelines for atrial fibrillation management.
    Charneski L; Hollands JM
    Pharmacotherapy; 2014 Nov; 34(11):1118-20. PubMed ID: 25284056
    [No Abstract]   [Full Text] [Related]  

  • 15. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist?
    Boom MS; Berghuis EM; Nieuwkerk PT; Pinedo S; Büller HR
    Neth J Med; 2015 Oct; 73(8):368-72. PubMed ID: 26478546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.